: Transplant patients are currently subjected to long term morbid therapy with immunosuppressive medications in order to prevent rejection of their grafts. For this reason, it is critical to devise therapies that are more specific and have improved side effect profiles. This will require a greater understanding into the mechanisms of allograft rejection. Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor known. An underappreciated biologic function of VEGF is its role in initiating and perpetuating an inflammatory response through the induction of proinflammatory chemokines. Furthermore, this function of VEGF has major implications for alloimmune recognition. This proposal seeks to elucidate the mechanisms by VEGF can exert an inflammatory response in the setting of alloimmune stimulation. The understanding gained through these experiments is likely to uncover new, more specific targets for the treatment of allograft rejection. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32HL073613-01
Application #
6649605
Study Section
Special Emphasis Panel (ZRG1-F07 (20))
Program Officer
Commarato, Michael
Project Start
2003-07-01
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$49,864
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115